NIAMS -- Accelerating Basic and Translational Research in Hidradenitis Suppurativa (R01, R21 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA) will support basic and translational studies aimed at understanding the etiology, and the cellular and molecular mechanisms, including the environmental, genetic, epigenetic, biologic, and immunologic factors causing and/or associated with Hidradenitis Suppurativa. The purpose is to accelerate discovery in this field of research and to apply new knowledge to improve patients’ condition and ultimately better control disease. This FOA intends to support a broad range of mechanistic studies using animal and human models, with an emphasis on multidisciplinary collaboration for rapid bench-to-bedside exchange of information and therapy development. This FOA is not intended to support applications proposing epidemiology studies and/or clinical trials.

Although this funding opportunity uses the R01 grant mechanism, it runs in parallel with a program announcement of identical scientific scope, PA-18-718, which uses the R21 grant mechanism.


  • R01 Due Dates: Feb. 5, Jun. 5, Oct. 5
  • R21 Due Dates: Feb. 16, Jun. 16, Oct. 16

PA-18-719 Expiration Date September 8, 2021

Agency Website



Amount Description

Application budgets must reflect the actual needs of the proposed project and is limited to direct costs of no more than $500,000 per year.
The scope of the proposed project should determine the project period. The maximum project period is 5 years.  

Funding Type





Medical - Basic Science
Medical - Translational

External Deadline

June 5, 2021